Pertuzumab

Drug Profile

Pertuzumab

Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab 2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech; Roche
  • Developer Chugai Pharmaceutical; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Japan Breast Cancer Research Group; Roche; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Gastric cancer; Ovarian cancer
  • Phase II Colorectal cancer
  • Discontinued Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 08 Jul 2017 Final efficacy and adverse events data from the phase III MARIANNE trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 05 Jun 2017 Efficacy and adverse events data from the phase III APHINITY trial in Breast cancer released by Genentech
  • 01 Jun 2017 Interim adverse events and efficacy data from the phase II PATRICIA trial in Breast cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top